TITLE

ATHENA: Dronedarone reduced CV hospitalization, death in AF

AUTHOR(S)
Rusk, Judith; Zipes, Douglas
PUB. DATE
June 2008
SOURCE
Cardiology Today;Jun2008, Vol. 11 Issue 6, p38
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article discusses dronedarone as a new investigational multi-channel blocker for the reduction of cardiovascular incidence or death in patients with atrial fibrillation (AF) or atrial flutter. Researchers found the drug reduces risk of cardiovascular hospitalization or death by 24%, risk of cardiovascular death by 30% including sudden death, and 16% less death from any cause than placebo. It mentions that participants who stopped taking dronedarone suffered from gastrointestinal side effects while those from the placebo group reported recurrent AF.
ACCESSION #
33119562

 

Related Articles

  • The Development of Atrial Flutter and Fibrillation. Habchabov, Rustam G. // European Journal of Cardiovascular Medicine;2013, Vol. 2 Issue 3, p194 

    Reasons of development of life-threatening arrhythmias that lead to sudden and total death in cases of cardiovascular diseases are still unclear, though cardiac research of this problem is conducted throughout the world. Damage of connective tissues insulation cover of the heart's conductive...

  • Diltiazem/sotalol interaction.  // Reactions Weekly;4/5/2008, Issue 1196, p15 

    The article describes the case of a 53-year-old man who had been receiving sustained-release diltiazem. The patient with a history of recurrent atrial flutter was hospitalised with palpitations. A mild mitral and tricuspid insufficiency was seen in an echocardiogram. He started receiving sotalol...

  • Restoring Sinus Rhythm in Patients With Atrial Flutter and Fibrillation: Pharmacologic or Electrical Cardioversion? Gallik, Donna; Altamirano, Jaime; Singh, Bramah N. // Journal of Cardiovascular Pharmacology & Therapeutics;Jun1997, Vol. 2 Issue 2, p135 

    The article reviews research on treatment options for the restoration and maintenance of sinus rhythm in patients with atrial flutter and fibrillation. Restoration of sinus rhythm can be done through pharmacologic or electrical cardioversion. Some of the drugs used for cardioversion were...

  • Posible valor pronóstico de la fibrilación y el flutter auricular en el síndrome de Brugada. Abud, Atilio; Goyeneche, Raúl; Carlessi, Adrian; Strada, Bruno; Becker, Carlos // Archivos de Cardiología de México;ene-mar2013, Vol. 83 Issue 1, p4 

    Objective: To analyze the specific risk for the variables: type 1 spontaneous pattern, type 1 induced pattern, type 1 pattern with spontaneous variability, syncope, family history of sudden death, atrial fibrillation and atrial flutter with the subsequent development of malignant arrhythmic...

  • Atrial flutter and fibrillation. Hammond, Cecile // RN;Jan84, Vol. 47 Issue 1, p102 

    Compares atrial flutter and atrial fibrillation. Cause of atrial flutter; Description of an atrial fibrillation; Risks of both diseases.

  • Untitled. Lakkireddy, Dhanunjaya; Natale, Andrea // JAFIB: Journal of Atrial Fibrillation;Aug/Sep2013, Vol. 6 Issue 2, p5 

    The article discusses various reports published within the issue including one by Y. Chan and colleague on predictors of atrial fibrillation (AF) after the ablation of a typical atrial flutter and another by Laurent Pison and colleague on hybrid strategies for AF ablation.

  • Dronedarone.  // AHFS Consumer Medication Information;Oct2017, p1 

    Dronedarone is used to treat people who have had atrial fibrillation (a heart rhythm disorder that may cause the heartbeat to be fast and irregular) or atrial flutter (a heart rhythm disorder that may cause the heartbeat to be fast but regular) during the past 6 months and who also have certain...

  • Lappaconitine.  // Reactions Weekly;12/15/2012, Issue 1432, p31 

    The article describes the case of a 45-year-old man, diagnosed with Wolff-Parkinson-White syndrome, who developed atrial flutter while under lappaconitine (allapinin) treatment regimen for arrhythmia.

  • Pharmacotherapy Options in Atrial Fibrillation: Focus on Vernakalant. Cheng, Judy W. M.; Rybak, Iwona // Clinical Medicine: Therapeutics;2009, Issue 1, p215 

    This article reviews the role of vernakalant in the management of atrial fi brillation (AF). Published data in English language were identifi ed from MEDLINE and Current Content database (both 1966 to January 30, 2009). Vernakalant is an antiarrhythmic agent with sodium and ultra-rapid potassium...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics